“At shareholder’s expense” is the nature of biopharma startups. Shareholders bear the cost of development and if development is successful shareholders/investors can make a fortune. Or, not. It’s been that way since the world’s first speculative corporation, Dutch East India. It’s always that way.
News 
Market Data 
Discover 
